Cited by 347Psychedelics and Drug StudiesForensic Toxicology and Drug AnalysisSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Psychedelics and Mental Health: A Population Study

Open access

Krebs, Teri S., Johansen, Pål-Ørjan·2013·PLoS ONE

DOI 10.1371/journal.pone.0063972PMC PMC3747247

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline. OBJECTIVE: To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population. METHOD: Data drawn from years 2001 to 2004 of the National Survey on Drug Use and Health consisted of 130,152 respondents, randomly selected to be representative of the adult population in the United States. Standardized screening measures for past year mental health included serious psychological distress (K6 scale), mental health treatment (inpatient, outpatient, medication, needed but did not receive), symptoms of eight psychiatric disorders (panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis), and seven specific symptoms of non-affective psychosis. We calculated weighted odds ratios by multivariate logistic regression controlling for a range of sociodemographic variables, use of illicit drugs, risk taking behavior, and exposure to traumatic events. RESULTS: 21,967 respondents (13.4% weighted) reported lifetime psychedelic use. There were no significant associations between lifetime use of any psychedelics, lifetime use of specific psychedelics (LSD, psilocybin, mescaline, peyote), or past year use of LSD and increased rate of any of the mental health outcomes. Rather, in several cases psychedelic use was associated with lower rate of mental health problems. CONCLUSION: We did not find use of psychedelics to be an independent risk factor for mental health problems.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0063972

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Screening for serious mental illness in the general population
Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., Howes, M. J., Normand, S.-L. T., Manderscheid, R. W., Walters, E. E., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.184 · Cited by 5,692
Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression
Vittinghoff, E., & McCulloch, C. E. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk052 · Cited by 4,359
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K. I., Isometsä, E. T., Pirkola, S. P., Partonen, T., Tuulio‐Henriksson, A., Hintikka, J., Kieseppä, T., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.19 · Cited by 1,523
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 1×
“LSD and psilocybin are consistently ranked in expert assessments as causing less harm to both individual users and society than alcohol, tobacco, and most other common recreational drugs [16–19].”
Background
European Monitoring Centre for Drugs and Drug Addiction
Anderson, M. (2014) · European Union regulations | European Encyclopedia of law · Cited by 1,214
Hallucinogens
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905

Flagged first, then by citations

Show all 58 references

Research works printed but not linked: 1

Laing R, Siegel JA, editors (2003) Hallucinogens: A Forensic Drug Handbook. Academic Press.

Sorted by citations

Psychedelics
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00269 · Cited by 470
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 410
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 359
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. S. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 330
Self-citation
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 270
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion
George, J. R., Michaels, T. I., Sevelius, J. M., & Williams, M. T. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.015 · Cited by 230
Psychedelics, personality and political perspectives.
Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1312643 · Cited by 226
Extended difficulties following the use of psychedelic drugs: A mixed methods study
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R. G., Luke, D. P., Michelle, K., & Prideaux, E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293349 · Cited by 220
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Unifying Theories of Psychedelic Drug Effects
Swanson, L. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00172 · Cited by 194
Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression
Lyons, T., & Carhart-Harris, R. L. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117748902 · Cited by 201
Neuroimaging the consciousness of self: Review, and conceptual-methodological framework
Frewen, P., Schroeter, M. L., Riva, G., Cipresso, P., Fairfield, B., Padulo, C., Kemp, A. H., Palaniyappan, L. K., Owolabi, M. O., Kusi‐Mensah, K., et al. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.01.023 · Cited by 186
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 186
Legal highs: staying on top of the flood of novel psychoactive substances
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314559539 · Cited by 162
Powerful substances in tiny amounts: An interview study of psychedelic microdosing
Johnstad, P. G. (2018) · Nordic Studies on Alcohol and Drugs · doi:10.1177/1455072517753339 · Cited by 155
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Substance-Induced Psychoses: An Updated Literature Review
Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.694863 · Cited by 135
Ethics and ego dissolution: the case of psilocybin
Smith, W. R., & Sisti, D. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2020-106070 · Cited by 146
Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice
Celidwen, Y., Redvers, N., Githaiga, C., Calambás, J., Bedriñana, K. G. A., Chindoy, M. E., Vitale, R., Rojas, J. N., Mondragón, D., Rosalío, Y. V., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100410 · Cited by 144
DARK Classics in Chemical Neuroscience: Psilocybin
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00186 · Cited by 159
The epidemiology of 5-methoxy- N, N -dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118769063 · Cited by 140
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
Serotonergic psychedelics and personality: A systematic review of contemporary research
Bouso, J. C., dos Santos, R. G., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.004 · Cited by 134
Epidemiology of hallucinogen use in the U.S. results from the National epidemiologic survey on alcohol and related conditions III
Shalit, N., Rehm, J. T., & Lev‐Ran, S. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.020 · Cited by 131
Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review
Reiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majić, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.012 · Cited by 122
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G. L., Giaroli, G., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 127
Co-Occurrence of Substance use Disorders with other Psychiatric Disorders: Implications for Treatment Services
Morisano, D., Babor, T. F., & Robaina, K. (2014) · Nordic Studies on Alcohol and Drugs · doi:10.2478/nsad-2014-0002 · Cited by 119
Toxicokinetics and Toxicodynamics of Ayahuasca alkaloids N,N-dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: clinical and forensic impact
Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á. (2020) · Pharmaceuticals · doi:10.3390/ph13110334 · Cited by 117
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 128
A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens
Barnett, B. S., Siu, W. O., & Pope, H. G. (2018) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000828 · Cited by 116
Case analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 128
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
The relationships of classic psychedelic use with criminal behavior in the United States adult population
Hendricks, P. S., Crawford, M. S., Cropsey, K. L., Copes, H., Sweat, N. W., Walsh, Z., & Pavela, G. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117735685 · Cited by 101
The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant
Sessa, B. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4713-7 · Cited by 98
d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders
Gregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 91
Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP
Livne, O., Shmulewitz, D., Walsh, C. A., & Hasin, D. S. (2022) · Addiction · doi:10.1111/add.15987 · Cited by 92
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
Nichols, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00043 · Cited by 91
Is LSD toxic?
Nichols, D. E., & Grob, C. S. (2018) · Forensic Science International · doi:10.1016/j.forsciint.2018.01.006 · Cited by 89
Psychedelics and health behaviour change
Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzøe, D., Douglass, H. M., Kettner, H., & Carhart-Harris, R. L. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211008554 · Cited by 109
Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison
Leptourgos, P., Fortier, M., Carhart-Harris, R. L., Corlett, P. R., Dupuis, D., Halberstadt, A. L., Kometer, M., Kozáková, E., Larøi, F., Noorani, T. N., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa117 · Cited by 90
Therapeutic Applications of Classic Hallucinogens
Bogenschutz, M. P., & Ross, S. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_464 · Cited by 92
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Self-reported negative outcomes of psilocybin users: A quantitative textual analysis
Bienemann, B., Ruschel, N. S., Campos, M. L. P., Negreiros, M. A., & Mograbi, D. C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229067 · Cited by 84
More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression
Lyons, T., & Carhart-Harris, R. L. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01721 · Cited by 77
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
Morton, E., Sakai, K., Ashtari, A., Pleet, M., Michalak, E. E., & Woolley, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221131997 · Cited by 78
Ayahuasca and public health: health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users
Ona, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1567961 · Cited by 76
Associations between lifetime classic psychedelic use and markers of physical health
Simonsson, O., Sexton, J. D., & Hendricks, P. S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121996863 · Cited by 74
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics
Tulver, K., Kaup, K., Laukkonen, R., & Aru, J. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103494 · Cited by 86
Psychedelics as a novel approach to treating autoimmune conditions
Thompson, C., & Szabó, A. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.10.001 · Cited by 71
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013583 · Cited by 71
Use of psilocybin (“mushrooms”) among US adults: 2015–2018
Yockey, R. A., & King, K. A. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00159 · Cited by 64
Self-transcendent experience: a grounded theory study
Garcia‐Romeu, A., Himelstein, S., & Kaminker, J. (2014) · Qualitative Research · doi:10.1177/1468794114550679 · Cited by 74
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211058923 · Cited by 65
Race as a component of set and setting: How experiences of race can influence psychedelic experiences
Neitzke‐Spruill, L. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.022 · Cited by 61
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
Argento, E., Strathdee, S. A., Tupper, K. W., Braschel, M. C., Wood, E., & Shannon, K. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016025 · Cited by 63
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
SANTOS, R. G. D., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. C. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s300656 · Cited by 73
Two Models of Legalization of Psychedelic Substances
Smith, W., & Appelbaum, P. S. (2021) · JAMA · doi:10.1001/jama.2021.12481 · Cited by 61
Pattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 70
Psychedelic drug use in healthy individuals: a review of benefits, costs, and implications for drug policy
Elsey, J. W. B. (2017) · Drug Science Policy and Law · doi:10.1177/2050324517723232 · Cited by 57
Psilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies
Sabé, M., Sulstarova, A., Glangetas, A., Pieri, M. D., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L. E., Seragnoli, F., Thorens, G., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02800-5 · Cited by 61
Lysergic Acid Diethylamide and Psilocybin for the Management of Patients with Persistent Pain: a Potential Role?
Whelan, A., & Johnson, M. I. (2018) · Pain Management · doi:10.2217/pmt-2017-0068 · Cited by 51
An introduction to psychedelic neuroscience
Calvey, T., & Howells, F. M. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.013 · Cited by 57
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Wolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 51
Review of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 60
Examining psychedelic-induced changes in social functioning and connectedness in a naturalistic online sample using the five-factor model of personality.
Weiss, B., Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L., & Erritzoe, D. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.749788 · Cited by 47
Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics
Rudin, D., Liechti, M. E., & Luethi, D. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113778 · Cited by 49
Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes
Matzopoulos, R., Morlock, R., Morlock, A., Lerer, B., & Lerer, L. B. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780696 · Cited by 57
Adolescent Psychedelic Use and Psychotic or Manic Symptoms
Simonsson, O., Mosing, M. A., Osika, W., Ullén, F., Larsson, H., Lu, Y., & Wesseldijk, L. W. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.0047 · Cited by 49
The role of substance use, smoking, and inflammation in risk for suicidal behavior
Chang, H. B., Munroe, S., Gray, K., Porta, G., Douaihy, A. B., Marsland, A. L., Brent, D. A., & Melhem, N. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.005 · Cited by 50
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Gandy, S. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.029 · Cited by 52
Counselors’ attitudes toward psychedelics and their use in therapy
Hearn, B., Brubaker, M. D., & Richardson, G. B. (2022) · Journal of Counseling & Development · doi:10.1002/jcad.12429 · Cited by 52
Naturalistic Psychedelic Use: A World Apart from Clinical Care
Glynos, N. G., Fields, C. W., Barron, J., Herberholz, M., Kruger, D. J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2108356 · Cited by 51
Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom
Honk, L., Stenfors, C. U. D., Goldberg, S. B., Hendricks, P. S., Osika, W., Dourron, H. M., Lebedev, A. V., Petrović, P., & Simonsson, O. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.197 · Cited by 48
Metabolic Fate of Hallucinogenic NBOMes
Leth-Petersen, S., Gabel-Jensen, C., Gillings, N., Lehel, S., Hansen, H. D., Knudsen, G. M., & Kristensen, J. L. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00450 · Cited by 43
Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study
Révész, D., Oña, G., Rossi, G. N., Rocha, J. M., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Bouso, J. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.687546 · Cited by 47
Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance‐related psychotic symptoms
Valeriani, G., Corazza, O., Bersani, F. S., Melcore, C., Metastasio, A., Bersani, G., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2431 · Cited by 41
Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy
Eleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39
“Both interventions have also successfully demonstrated reductions in clinical symptomatology in healthy individuals (65, 66).”
Background
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences
Orłowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089034 · Cited by 41
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723001514 · Cited by 48
Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary
Sessa, B., & Fischer, F. M. (2015) · Drug Science Policy and Law · doi:10.1177/2050324515578080 · Cited by 40
Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences
Johnstad, P. G. (2020) · Nordic Studies on Alcohol and Drugs · doi:10.1177/1455072520963787 · Cited by 40
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy
Koslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 42

Authors: Krebs, T. S., & Johansen, P.-Ø.
Affiliations: Norwegian University of Science and Technology (NO)
Corresponding author: Krebs, Teri S.
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2013-08-19
Volume: 8
Issue: 8
Pages: e63972
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0063972
PMC: PMC3747247
OpenAlex: W2014761647
Cited by: 347
References: 58
Citations by year: 2026: 24 · 2025: 25 · 2024: 37 · 2023: 53 · 2022: 40 · 2021: 41 · 2020: 17 · 2019: 17 · 2018: 30 · 2017: 19 · 2016: 20 · 2015: 16 · 2014: 6 · 2013: 2
FWCI: 16.32
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Funders: Norges Forskningsråd (rcn-foriss-185924)
Substance Abuse and Mental Health Services Administration
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords: psychedelics, LSD, psilocybin, mescaline, peyote, mental health, serious psychological distress, mental illness, non-affective psychosis, lifetime drug use, risk factors for mental illness, National Survey on Drug Use and Health
MeSH terms: Adolescent, Adult, Mental Disorders, Data Collection, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Mental Health, Mescaline, Middle Aged, Psilocybin, Risk Factors, United States, Odds Ratio

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Psychedelics and Mental Health: A Population Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks